Gene transfer and antisense nucleic acid techniques

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Attempts to suppress a harmful genetic trait by antisense means, or to restore a normal phenotype by gene transfer, attract much publicity. This is especially the case where clinical trials incorporating such methodologies have been initiated, such as antisense oligonucleotide therapies for some types of leukaemia, antisense gene-transfer therapy for a form of lung cancer, and gene-transfer therapies for adenosine deaminase deficiency, severe combined immunodeficiency disease, and various forms of cancer including brain tumours and melanoma. However, translation of laboratory success into treatment or control of disease is unlikely to be straightforward. Here, Nick Miller and Richard Vile summarize the rationale, problems and potential of such techniques as applied to parasitic disease.

Original languageEnglish (US)
Pages (from-to)92-97
Number of pages6
JournalParasitology Today
Volume10
Issue number3
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Brain Neoplasms
Genetic Therapy
Nucleic Acids
Severe Combined Immunodeficiency
Parasitic Diseases
Antisense Oligonucleotides
Neoplasm Genes
Genes
Melanoma
Lung Neoplasms
Leukemia
Clinical Trials
Phenotype
Therapeutics
Severe combined immunodeficiency due to adenosine deaminase deficiency

ASJC Scopus subject areas

  • Parasitology

Cite this

Gene transfer and antisense nucleic acid techniques. / Miller, N.; Vile, Richard Geoffrey.

In: Parasitology Today, Vol. 10, No. 3, 1994, p. 92-97.

Research output: Contribution to journalArticle

@article{160af6a68ddd4ef299a87c4af169ba1d,
title = "Gene transfer and antisense nucleic acid techniques",
abstract = "Attempts to suppress a harmful genetic trait by antisense means, or to restore a normal phenotype by gene transfer, attract much publicity. This is especially the case where clinical trials incorporating such methodologies have been initiated, such as antisense oligonucleotide therapies for some types of leukaemia, antisense gene-transfer therapy for a form of lung cancer, and gene-transfer therapies for adenosine deaminase deficiency, severe combined immunodeficiency disease, and various forms of cancer including brain tumours and melanoma. However, translation of laboratory success into treatment or control of disease is unlikely to be straightforward. Here, Nick Miller and Richard Vile summarize the rationale, problems and potential of such techniques as applied to parasitic disease.",
author = "N. Miller and Vile, {Richard Geoffrey}",
year = "1994",
doi = "10.1016/0169-4758(94)90006-X",
language = "English (US)",
volume = "10",
pages = "92--97",
journal = "Trends in Parasitology",
issn = "1471-4922",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Gene transfer and antisense nucleic acid techniques

AU - Miller, N.

AU - Vile, Richard Geoffrey

PY - 1994

Y1 - 1994

N2 - Attempts to suppress a harmful genetic trait by antisense means, or to restore a normal phenotype by gene transfer, attract much publicity. This is especially the case where clinical trials incorporating such methodologies have been initiated, such as antisense oligonucleotide therapies for some types of leukaemia, antisense gene-transfer therapy for a form of lung cancer, and gene-transfer therapies for adenosine deaminase deficiency, severe combined immunodeficiency disease, and various forms of cancer including brain tumours and melanoma. However, translation of laboratory success into treatment or control of disease is unlikely to be straightforward. Here, Nick Miller and Richard Vile summarize the rationale, problems and potential of such techniques as applied to parasitic disease.

AB - Attempts to suppress a harmful genetic trait by antisense means, or to restore a normal phenotype by gene transfer, attract much publicity. This is especially the case where clinical trials incorporating such methodologies have been initiated, such as antisense oligonucleotide therapies for some types of leukaemia, antisense gene-transfer therapy for a form of lung cancer, and gene-transfer therapies for adenosine deaminase deficiency, severe combined immunodeficiency disease, and various forms of cancer including brain tumours and melanoma. However, translation of laboratory success into treatment or control of disease is unlikely to be straightforward. Here, Nick Miller and Richard Vile summarize the rationale, problems and potential of such techniques as applied to parasitic disease.

UR - http://www.scopus.com/inward/record.url?scp=0028157020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028157020&partnerID=8YFLogxK

U2 - 10.1016/0169-4758(94)90006-X

DO - 10.1016/0169-4758(94)90006-X

M3 - Article

C2 - 15275488

AN - SCOPUS:0028157020

VL - 10

SP - 92

EP - 97

JO - Trends in Parasitology

JF - Trends in Parasitology

SN - 1471-4922

IS - 3

ER -